- Home
- GALT
as 05-20-2024 2:32pm EST
$.
-
$.
-.%
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | NORCROSS |
| Market Cap: | 200.6M | IPO Year: | N/A |
| Target Price: | $11.00 | AVG Volume (30 days): | 184.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.28 - $4.27 | Next Earning Date: | 05-15-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Stock Insider Trading Activity of Galectin Therapeutics Inc. (GALT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Zordani Richard A. Jr. | GALT | Director | Apr 30 '24 | Buy | $3.52 | 1,000 | $3,520.00 | 1,000 | SEC Form 4 |
| LEWIS JOEL | GALT | President and CEO | Apr 24 '24 | Buy | $3.39 | 1,000 | $3,390.00 | 2,000 | SEC Form 4 |
Latest Galectin Therapeutics Inc. News
GALT Breaking Stock News: Dive into GALT Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
GlobeNewswire
7 days ago
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 04/23/2024
GlobeNewswire
a month ago
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
GuruFocus.com
2 months ago
Galectin Therapeutics Inc (GALT) Reports 2023 Financial Results and Business Developments
GlobeNewswire
2 months ago
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
GlobeNewswire
2 months ago
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development
Simply Wall St.
3 months ago